Recon: Lilly’s weekly insulin found comparable to daily products; Biogen, Ionis end ALS drug program after early-stage miss
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeEuropean Medicines Agency (EMA)GlobalManufacturingMedical DevicesNorth AmericaPharmaceuticalsProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)